Glucagon-like peptide-1 receptor agonists “may well be disease-modifying” in sufferers with knee osteoarthritis and kind 2 diabetes if remedy is continued for a enough length, in keeping with information.
The researchers, who printed their findings within the Annals of the Rheumatic Sicknesses, added that the outcome could also be mediated through weight reduction.
“Maintaining weight keep an eye on in the long run stays a big problem for the overall inhabitants together with [knee OA (KOA)] sufferers,” Hongyi Zhu, PhD, of the dep. of orthopedics at Shanghai 6th Folks’s Sanatorium, in China,
